MedDataX Logo

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer

NCT ID: NCT01311037

Last Updated: 2011-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Breast Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Premenopausal Women with Advanced Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GnRh Analogue and Aromatase Inhibitor

GnRh Analogue and Aromatase Inhibitor

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Receptor Positive Premenopausal Women with Advanced Breast Cancer.

Exclusion Criteria

* Any woman other than diagnosis of Receptor Positive Premenopausal with Advanced Breast Cancer.
Minimum Eligible Age

45 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King Faisal Specialist Hospital & Research Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Al Sayed, M.D.

Role: PRINCIPAL_INVESTIGATOR

KFSH & RC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kfsh & Rc

Riyadh, , Saudi Arabia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Al Sayed, M.D.

Role: CONTACT

Phone: +966-1-4423949

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAC# 2081-064

Identifier Type: -

Identifier Source: secondary_id

RAC# 2081-064

Identifier Type: -

Identifier Source: org_study_id